Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Actacel
- Development stage
- Phase 3
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Actacel is a quadrivalent combination vaccine developed by Sanofi Pasteur for the active immunization of infants and children against diphtheria, tetanus, pertussis, and invasive diseases caused by *Haemophilus influenzae* type b (Hib). The vaccine combines diphtheria and tetanus toxoids with acellular pertussis antigens—specifically pertussis toxoid (PT), filamentous hemagglutinin (FHA), and fimbriae types 2 and 3 (FIM2/3)—and the Hib capsular polysaccharide (polyribosylribitol phosphate) conjugated to a tetanus protein carrier (PRP-T). By integrating these four components into a single injection, Actacel simplifies pediatric vaccination schedules and improves compliance while maintaining immunogenicity comparable to separate DTaP and Hib vaccines. It is primarily used in primary and booster vaccination series for healthy infants.
- Brand names
- Actacel
- Other names
- DTaP-Hib vaccineDTaP//PRP-T Combined VaccineDiphtheria-Tetanus-acellular Pertussis-Haemophilus influenzae type b conjugate vaccine
02
Targets
PRN (Pertactin)FHA (Filamentous hemagglutinin)Diphtheria toxinFIM2/FIM3 (Fimbriae types 2 and 3)TT (Tetanus toxoid)
Beyond the preview
Go deeper on Actacel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Actacel.